Jennison Associates
DFTX icon

Jennison Associates’s Definium Therapeutics DFTX Stock Holding History

Jennison Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.13M Buy
45,375
+5,418
+14% +$134K ﹤0.01% 450
2026
Q1 		$755K Sell
39,957
-13,828
-26% -$235K ﹤0.01% 520
2025
Q4 		$720K Buy
+53,785
New +$666K ﹤0.01% 535

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Jennison Associates's DFTX Position: Q2 2026 in Review

Jennison Associates increased its Definium Therapeutics (DFTX) stake by 14% in Q2 2026, buying an estimated $134K and bringing the position to 45,375 shares worth $2.13M. The position accounts for ﹤0.01% of the portfolio, ranked #450.

Jennison Associates first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Jennison Associates held 45,375 shares of Definium Therapeutics worth $2.13M as of Q2 2026.
  • Jennison Associates bought 5,418 Definium Therapeutics shares in Q2 2026, an estimated $134K.
  • Definium Therapeutics made up ﹤0.01% of Jennison Associates's portfolio in Q2 2026, its #450 holding.
  • Jennison Associates first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.